Compositions and methods related to tauopathy
Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2.
1. An antibody preparation comprising a monoclonal antibody that specifically binds to SEQ ID NO:11 and requires no amino acid residues outside of SEQ ID NO:11 to specifically bind to SEQ ID NO:11.
2. A method comprising:
contacting a biological sample comprising cerebral spinal fluid from a subject with an antibody preparation of claim 1 ; and
detecting a ligand in the sample that specifically binds the antibody preparation.
3. The method of claim 2 wherein the subject exhibits at least one symptom or clinical sign of a tauopathic condition.
4. The method of claim 3 wherein the tauopathic condition is Alzheimer's disease.
5. The method of claim 2 wherein the subject exhibits no symptom or clinical sign of a tauopathic condition.
6. The method of claim 2 wherein the tauopathic condition is Alzheimer's disease.